Sanofi launches diabetes drug Soliqua in India
Kolkata: Sanofi India Limited has launched its’ new diabetes drug Soliqua after having received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Living with type 2 diabetes could get complicated and burdensome.
A large category of patients on multiple medications have to deal with weight gain, hypoglycemia and multiple injection pricks, even as they struggle to keep their blood sugar under control.
The need of the hour is to help them reach and maintain optimal glycemic (blood sugar) control, keeping such worries at bay.
Soliqua simplifies these complexities by offering patients a sustained blood-sugar control, all day, in a simple, once-daily injection that can seamlessly fit into their lifestyle and help them break through the complexity of their diabetes management.
Cyrus Aibara Head – Diabetes Business Unit, Sanofi (India), “Over 100 million Indians are living with type 2 diabetes and its complexities. Of these, over 60% people are living with uncontrolled blood sugar levels and have a higher risk of developing complications, despite being on treatment including multiple OADs (oral anti-diabetics) over a long period of time.
“The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively.”
Dr. Shalini Menon Country Medical Lead, Sanofi (India) said, “Despite the advances in diabetes care, many people living with type 2 diabetes are unable to reach their sugar goals. Fear of hypoglycemia, weight gain and multiple injections can be barriers to effective treatment with insulins.
“In clinical trials, the combination injectable Soliqua has demonstrated effective sugar control, without weight gain and with lower risk of hypoglycemia, compared to twice daily premix insulins.
“Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
“This global innovation is now accessible at a nominal therapy cost of INR 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.”
IBNS
Senior Staff Reporter at Northeast Herald, covering news from Tripura and Northeast India.
Related Articles
Vijaya Diagnostic Centre inaugurates State-of-the-Art Centre featuring first advanced 3 Tesla MRI in Kolkata
Kolkata/IBNS: Vijaya Diagnostic Centre, India’s largest B2C-focused integrated diagnostic chain, on Thursday announced the grand opening of its state-of-the-art diagnostic centre in Kasba, Kolkata.
More than 720,000 people commit suicide every year: WHO
More than 720,000 people commit suicide every year and many more attempt it. Now the head of the UN’s World Health Organization (WHO) is calling for “shifting the narrative” on the issue “to challenge harmful myths, reduce stigma and foster compassionate conversations.”
Obesity has surpassed underweight: UNICEF report
For the first time in history, obesity has surpassed those underweight as the most common form of malnutrition among school-age children and adolescents worldwide, UNICEF revealed in a new report on Tuesday.
India joins multiple nations in witnessing rare celestial event 'Blood Moon'
Thousands of skywatchers in several nations across the world, including in India, witnessed the rare celestial event, ‘Blood Moon’ or the total lunar eclipse, on Sunday.
Latest News
Over 1.5 crore passengers travelled in trains operated so far in festival season
CM emphasizes strengthening Kisan Rail, promoting Agri-based branding in NE
Tripura assembly delegation on five-day study tour to Gujarat
Rs 303 crore push for agri markets as Tripura targets self-reliance, jobs: Minister
